TherapeuticsMD (TXMD) Reports In-Line Q4 EPS

TherapeuticsMD (NASDAQ: TXMD) reported Q4 EPS of ($0.17), in-line with the analyst estimate of ($0.17). Revenue for the quarter came in at $5.09 million versus the consensus estimate of $5 million.

For earnings history and earnings-related data on TherapeuticsMD (TXMD) click here.

You May Also Be Interested In

• Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
• Raymond James Reiterates Underperform Rating on Lennar (LEN)
• DA Davidson Reiterates Buy Rating on Vulcan Materials Company (VMC)